CorMedix Inc. Rings the Nasdaq Stock Market Closing Bell

CorMedix (Nasdaq: CRMD), visits the Nasdaq MarketSite in Times Square. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions. The Company recently announced that the U.S. Food and Drug Administration (FDA) has approved DefenCath® (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In honor of the occasion, Joe Todisco, CEO of CorMedix, rings the Closing Bell.